Scientists test supercharged immune cells against deadly brain tumors
NCT ID NCT07244666
Summary
This early-stage study is testing whether modified immune cells can safely fight recurrent glioblastoma, an aggressive brain cancer. Researchers will collect patients' own immune cells, genetically engineer them to target a specific cancer marker, and reinfuse them. The study will first assess safety in 36 patients with recurrent glioblastoma, then look for early signs of tumor shrinkage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.